National Health Act 1953 - Amendment determination under subsections 85AB(1) and 85AC(1) - drugs on F1 and drugs in Part A of F2 (No. PB 89 of 2009)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), aiming to ensure that all Australians have reliable, timely, and affordable access to a broad range of medicines. To refine the administration and regulation of pharmaceutical benefits under the PBS, the Act was amended through the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2007. This amendment introduced the concept of formularies, specifically F1 and F2, to classify drugs based on their therapeutic groups and market competition, thereby facilitating statutory price reductions, price disclosure, and a guarantee of supply. The Act allows the Minister to determine by legislative instrument which listed drugs are assigned to these formularies, ensuring the provisions of the Act are applied appropriately. The explanatory statement outlines an amendment determination under the National Health Act 1953, adjusting the formulary classifications for specific drugs, namely "Alendronic acid with colecalciferol" and "Topiramate," to comply with the statutory criteria for inclusion in F2 and Part A of F2. This amendment, effective from 1 October 2009, reflects the policy objective of enhancing the efficiency and equity of the PBS by better managing pharmaceutical costs and ensuring broader access to essential medications.

Scope and Application

The National Health Act 1953, as amended, serves as the legislative framework for the Pharmaceutical Benefits Scheme (PBS), which ensures Australians have access to a broad spectrum of affordable and timely medicines. The Act applies to all entities and individuals involved in the provision and administration of pharmaceutical benefits, including pharmaceutical companies, healthcare providers, and patients. Its jurisdiction extends across the Commonwealth, providing a national scope for the regulation of listed drugs under the PBS. The Act's provisions include the classification of drugs into formularies, specifically F1 and F2, with the latter further divided into Part A and Part T. These classifications are pivotal for determining the application of statutory price reductions, price disclosure requirements, and guarantees of supply. The Act empowers the Minister to determine through legislative instruments the classification of listed drugs into these formularies, with specific criteria governing the placement of drugs into F1 or F2 and subsequently into Part A or Part T of F2. The Act does not explicitly state exclusions or thresholds, but the application of its provisions is contingent on the drug being declared as a listed drug under the Act. The geographic and jurisdictional reach of the Act is national, impacting all stakeholders within the Australian healthcare system. The application of the Act may be extended or restricted through subordinate instruments, such as regulations, which provide further detail on the implementation of the scheme.

Key Provisions

The primary operative sections of this legislation pertain to the amendment of the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953. Specifically, section 85AB(1) and section 85AC(1) allow the Minister to determine by legislative instrument the placement of listed drugs on either Formulary F1 or Formulary F2, and subsequently, within Formulary F2, either Part A or Part T. Section 85(1) mandates that benefits are to be provided by the Commonwealth in accordance with Part VII of the Act regarding pharmaceutical benefits. Section 85(2) empowers the Minister to declare drugs and medicinal preparations that are subject to Part VII, while sections 85(3), 85(5), and 85(6) allow the Minister to determine the form, administration, and brand of listed drugs, respectively. The amendments outlined in this instrument determine that the listed drugs “Alendronic acid with colecalciferol” and “Topiramate” are placed on F2 and specifically in Part A of F2, effective from 1 October 2009. The Act imposes several obligations and requirements on the parties it governs. Pharmaceutical companies must ensure that their listed drugs comply with the criteria set out in the Act for their placement on either Formulary F1 or Formulary F2. These criteria include the absence of bioequivalent or biosimilar listed brands and specific therapeutic group considerations. The Minister's role involves making determinations based on these criteria and ensuring that the drugs are placed appropriately within the formularies. Additionally, the Act mandates that the Therapeutic Goods Administration and the Pharmaceutical Benefits Advisory Committee be consulted when drugs are listed on the PBS, with recommendations for formulary placement made by the latter. Under the Act, several offences, penalties, or consequences may arise for breach of its provisions. While specific penalties are not detailed in the text provided, breaches of the Act could potentially lead to civil or criminal consequences, including fines and other sanctions. The Act also includes provisions for statutory price reductions, price disclosure, and guarantee of supply, which apply to drugs on F2. These provisions are particularly relevant for drugs in Parts A and T of F2, where price competition between brands is high. The Act's framework is designed to ensure that the PBS provides reliable, timely, and affordable access to a wide range of medicines for all Australians. In summary, this legislation amends the placement of specific listed drugs within the PBS framework by determining that “Alendronic acid with colecalciferol” and “Topiramate” are on F2 and in Part A of F2. This is effective from 1 October 2009 and follows the criteria set out in the Act. Pharmaceutical companies are required to comply with these determinations, and the Minister plays a key role in ensuring that drugs are placed appropriately within the formularies. While specific penalties for breach are not detailed, the Act provides a robust framework for the administration of pharmaceutical benefits under the PBS.